



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 4, 2006

Signature: 

(Sharon M. Sintich)

Docket No.: 30847/2051-004  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Helgadottir *et al.*

Application No.: 10/769,744

Confirmation No.: 6429

Filed: January 30, 2004

Art Unit: 1646

For: Susceptibility Gene for Myocardial Infarction, Stroke,  
and PAOD; Methods of Treatment

Examiner: Not Yet Assigned

**SEQUENCE STATEMENT PURSUANT TO 37 CFR § 1.825(A) AND(B) AND  
SUBMISSION OF COMPACT DISC OF SUBSTITUTE SEQUENCE LISTING  
(37 CFR § 1.52(e))**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Submitted herewith in lieu of a paper copy of the substitute Sequence Listing, and in accordance with 37 CFR 1.52(e), are three (3) copies of CD-R compact discs containing the sequence listing labeled Copy 1, Copy 2 and computer-readable form (CRF) in accordance with 37 CFR § 1.824. The compact discs are formatted from an IBM-PC and are compatible with MS-Windows. The compact discs contain the following file: 2051004.txt, containing 428KB. This file was created on December 1, 2006.

The substitute Sequence Listing contained on the enclosed CDs complies with the requirements of 37 C.F.R. §1.52 and 37 C.F.R. §§1.821-1.825 and is identical to the paper sequence listing as originally filed. In accordance with 37 C.F.R. §1.825(a) and (b), I hereby state that the content of the computer-readable form (CRF) is identical to the content of the CD-R compact discs, and does not contain new matter.

Dated: December 4, 2006

Respectfully submitted,

By 

Sharon M. Sintich

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Agent for Applicant

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 4, 2006

Signature:

(Sharon M. Sintich)

Docket No.: 30847/2051-004  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Helgadottir et al.

Confirmation No.: 6429

Application No.: 10/769,744

Art Unit: 1646

Filed: January 30, 2004

Examiner: Not Yet Assigned

For: SUSCEPTIBILITY GENE FOR  
MYOCARDIAL INFARCTION, STROKE,  
AND PAOD; METHODS OF TREATMENT

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO  
ACID SEQUENCE DISCLOSURE**

MS Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This amendment is in response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed October 3, 2006. The Notice required the submission of a replacement sequence listing statement in compliance with 37 C.F.R. § 1.821-1.825. This response is timely filed.


Prior to examination on the merits, please amend the above-identified patent application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Sequence Listing** begin on page 3 of this paper.

**Remarks** begin on page 4 of this paper.

IFW



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/769,744	01/30/2004	Anna Helgadottir	2345.2051-004

04743  
 MARSHALL, GERSTEIN & BORUN LLP  
 233 S. WACKER DRIVE, SUITE 6300  
 SEARS TOWER  
 CHICAGO, IL 60606

CONFIRMATION NO. 6429  
 FORMALITIES  
 LETTER

Date Mailed: 10/03/2006

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).


- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

To Download Patentin Software, visit <http://www.uspto.gov/web/patents/software.htm>  
 For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Replies should be mailed to: Mail Stop Missing Parts  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*

A handwritten signature in black ink, appearing to be "J. Smith", is written over a horizontal line.

Office of Initial Patent Examination (571) 272-4000, or 1-800-PTO-9199, or 1-800-972-6382  
PART 2 - COPY TO BE RETURNED WITH RESPONSE